Top

Published in:

01-07-2019 | Original Article

Identification of Differentially Expressed Genes under the Regulation of Transcription Factors in Osteosarcoma

Authors: Yang Liu, Jianzhong Guan, Xiaotian Chen

Published in: Pathology & Oncology Research | Issue 3/2019

Abstract

The present study was to investigate and identify the differentially expressed genes (DEGs) in the transcriptional regulatory network of osteosarcoma (OS). The gene expression dataset from Gene Expression Omnibus (GEO) datasets was downloaded. DEGs were identified and their functional annotation was also conducted. In addition, differentially expressed transcription factors (TFs) and the regulatory genes were identified. The electronic validation was used to verify the expression of selected genes. The integrated analysis led to 932 DEGs. The results of functional annotation indicated that these DEGs significantly enriched in the p53 signaling pathway, Jak-STAT signaling pathway and Wnt signaling pathway. ZNF354C, NFIC, NFATC2, SP2, FOXO3, EGR1, ZEB1, RREB1, EGR2 and SRF were covered by most TFs. The expression levels of NFIC and EGR2 in electronic validation were compatible with our bio-informatics result. In conclusion, the deregulation of these genes may provide valuable information in understanding the underlying molecular mechanism in the OS.

Koyani CN, Kitz K, Rossmann C, Bernhart E, Huber E, Trummer C, Windischhofer W, Sattler W, Malle E (2016) Activation of the MAPK/Akt/Nrf2-Egr1/HO-1-GCLc axis protects MG-63 osteosarcoma cells against 15d-PGJ2-mediated cell death. Biochem Pharmacol 104:29–41. https://doi.org/10.1016/j.bcp.2016.01.011 CrossRefPubMedPubMedCentral

Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer 115(7):1531–1543. https://doi.org/10.1002/cncr.24121 CrossRefPubMed

Ottaviani G, Jaffe N (2009) The epidemiology of osteosarcoma. Cancer Treat Res 152:3–13. https://doi.org/10.1007/978-1-4419-0284-9_1 CrossRefPubMed

Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G (2006) Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 32(6):423–436. https://doi.org/10.1016/j.ctrv.2006.05.005 CrossRefPubMed

Gorlick R (2009) Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res 152:467–478. https://doi.org/10.1007/978-1-4419-0284-9_27 CrossRefPubMed

Mirabello L, Koster R, Moriarity BS, Spector LG, Meltzer PS, Gary J, Machiela MJ, Pankratz N, Panagiotou OA, Largaespada D, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, de Toledo SR, Petrilli AS, Patino-Garcia A, Sierrasesumaga L, Lecanda F, Andrulis IL, Wunder JS, Gokgoz N, Serra M, Hattinger C, Picci P, Scotlandi K, Flanagan AM, Tirabosco R, Amary MF, Halai D, Ballinger ML, Thomas DM, Davis S, Barkauskas DA, Marina N, Helman L, Otto GM, Becklin KL, Wolf NK, Weg MT, Tucker M, Wacholder S, Fraumeni JF Jr, Caporaso NE, Boland JF, Hicks BD, Vogt A, Burdett L, Yeager M, Hoover RN, Chanock SJ, Savage SA (2015) A genome-wide scan identifies variants in NFIB associated with metastasis in patients with osteosarcoma. Cancer Discov 5(9):920–931. https://doi.org/10.1158/2159-8290.cd-15-0125 CrossRefPubMedPubMedCentral

Johnson DS, Mortazavi A, Myers RM, Wold B (2007) Genome-wide mapping of in vivo protein-DNA interactions. Science (New York, NY) 316(5830):1497–1502. https://doi.org/10.1126/science.1141319 CrossRef

Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, Yefanov A, Lee H, Zhang N, Robertson CL, Serova N, Davis S, Soboleva A (2013) NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res 41(Database issue):D991–D995. https://doi.org/10.1093/nar/gks1193 CrossRefPubMed

Knuppel R, Dietze P, Lehnberg W, Frech K, Wingender E (1994) TRANSFAC retrieval program: a network model database of eukaryotic transcription regulating sequences and proteins. J Comput Biol 1(3):191–198CrossRefPubMed

10.

Gibbs CP Jr, Weber K, Scarborough MT (2002) Malignant bone tumors. Instr Course Lect 51:413–428PubMed

11.

Scotlandi K, Picci P, Kovar H (2009) Targeted therapies in bone sarcomas. Curr Cancer Drug Targets 9(7):843–853CrossRefPubMed

12.

Ragland BD, Bell WC, Lopez RR, Siegal GP (2002) Cytogenetics and molecular biology of osteosarcoma. Lab Investig 82(4):365–373CrossRefPubMed

13.

Clark JC, Dass CR, Choong PF (2008) A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 134(3):281–297. https://doi.org/10.1007/s00432-007-0330-x CrossRefPubMed

14.

Meng F, Zhu L, Huang W, Irwin DM, Zhang S (2016) Bats: body mass index, forearm mass index, blood glucose levels and SLC2A2 genes for diabetes. Sci Rep 6:29960. https://doi.org/10.1038/srep29960 CrossRefPubMedPubMedCentral

15.

Fei Q, Lin J, Meng H, Wang B, Yang Y, Wang Q, Su N, Li J, Li D (2016) Identification of upstream regulators for synovial expression signature genes in osteoarthritis. Joint Bone Spine 83(5):545–551. https://doi.org/10.1016/j.jbspin.2015.09.001 CrossRefPubMed

16.

Luo Y, Deng Z, Chen J (2013) Pivotal regulatory network and genes in osteosarcoma. Arch Med Sci 9(3):569–575. https://doi.org/10.5114/aoms.2012.30956 CrossRefPubMed

17.

Horsley V, Friday BB, Matteson S, Kegley KM, Gephart J, Pavlath GK (2001) Regulation of the growth of multinucleated muscle cells by an NFATC2-dependent pathway. J Cell Biol 153(2):329–338CrossRefPubMedPubMedCentral

18.

Wang J, Gardner BM, Lu Q, Rodova M, Woodbury BG, Yost JG, Roby KF, Pinson DM, Tawfik O, Anderson HC (2009) Transcription factor Nfat1 deficiency causes osteoarthritis through dysfunction of adult articular chondrocytes. J Pathol 219(2):163–172. https://doi.org/10.1002/path.2578 CrossRefPubMedPubMedCentral

19.

Bauer W, Rauner M, Haase M, Kujawski S, Arabanian LS, Habermann I, Hofbauer LC, Ehninger G, Kiani A (2011) Osteomyelosclerosis, anemia and extramedullary hematopoiesis in mice lacking the transcription factor NFATc2. Haematologica 96(11):1580–1588. https://doi.org/10.3324/haematol.2011.042515 CrossRefPubMedPubMedCentral

20.

Kingsley C, Winoto A (1992) Cloning of GT box-binding proteins: a novel Sp1 multigene family regulating T-cell receptor gene expression. Mol Cell Biol 12(10):4251–4261CrossRefPubMedPubMedCentral

21.

Kim TH, Chiera SL, Linder KE, Trempus CS, Smart RC, Horowitz JM (2010) Overexpression of transcription factor sp2 inhibits epidermal differentiation and increases susceptibility to wound- and carcinogen-induced tumorigenesis. Cancer Res 70(21):8507–8516. https://doi.org/10.1158/0008-5472.can-10-1213 CrossRefPubMedPubMedCentral

22.

Ambrogini E, Almeida M, Martin-Millan M, Paik JH, Depinho RA, Han L, Goellner J, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC (2010) FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metab 11(2):136–146. https://doi.org/10.1016/j.cmet.2009.12.009 CrossRefPubMedPubMedCentral

23.

Almeida M (2011) Unraveling the role of FoxOs in bone--insights from mouse models. Bone 49(3):319–327. https://doi.org/10.1016/j.bone.2011.05.023 CrossRefPubMedPubMedCentral

24.

Turrel-Davin F, Tournadre A, Pachot A, Arnaud B, Cazalis MA, Mougin B, Miossec P (2010) FoxO3a involved in neutrophil and T cell survival is overexpressed in rheumatoid blood and synovial tissue. Ann Rheum Dis 69(4):755–760. https://doi.org/10.1136/ard.2009.109991 CrossRefPubMed

25.

Lee JC, Espeli M, Anderson CA, Linterman MA, Pocock JM, Williams NJ, Roberts R, Viatte S, Fu B, Peshu N, Hien TT, Phu NH, Wesley E, Edwards C, Ahmad T, Mansfield JC, Gearry R, Dunstan S, Williams TN, Barton A, Vinuesa CG, Parkes M, Lyons PA, Smith KG (2013) Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell 155(1):57–69. https://doi.org/10.1016/j.cell.2013.08.034 CrossRefPubMedPubMedCentral

26.

Matsunoshita Y, Ijiri K, Ishidou Y, Nagano S, Yamamoto T, Nagao H, Komiya S, Setoguchi T (2011) Suppression of osteosarcoma cell invasion by chemotherapy is mediated by urokinase plasminogen activator activity via up-regulation of EGR1. PLoS One 6(1):e16234. https://doi.org/10.1371/journal.pone.0016234 CrossRefPubMedPubMedCentral

27.

Liu Y, Zhang N, Wang Y, Xu M, Liu N, Pang X, Cao J, Ma N, Pang H, Liu L, Zhang H (2012) Zinc finger E-box binding homeobox 1 promotes invasion and bone metastasis of small cell lung cancer in vitro and in vivo. Cancer Sci 103(8):1420–1428. https://doi.org/10.1111/j.1349-7006.2012.02347.x CrossRefPubMedPubMedCentral

28.

Shen A, Zhang Y, Yang H, Xu R, Huang G (2012) Overexpression of ZEB1 relates to metastasis and invasion in osteosarcoma. J Surg Oncol 105(8):830–834. https://doi.org/10.1002/jso.23012 CrossRefPubMed

29.

Nitz MD, Harding MA, Smith SC, Thomas S, Theodorescu D (2011) RREB1 transcription factor splice variants in urologic cancer. Am J Pathol 179(1):477–486. https://doi.org/10.1016/j.ajpath.2011.03.038 CrossRefPubMedPubMedCentral

30.

Liu H, Hew HC, Lu ZG, Yamaguchi T, Miki Y, Yoshida K (2009) DNA damage signalling recruits RREB-1 to the p53 tumour suppressor promoter. Biochem J 422(3):543–551. https://doi.org/10.1042/bj20090342 CrossRefPubMed

31.

Li X, Zhang Z, Yu M, Li L, Du G, Xiao W, Yang H (2013) Involvement of miR−20a in promoting gastric cancer progression by targeting early growth response 2 (EGR2). Int J Mol Sci 14(8):16226–16239. https://doi.org/10.3390/ijms140816226 CrossRefPubMedPubMedCentral

32.

Unoki M, Nakamura Y (2001) Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 20(33):4457–4465. https://doi.org/10.1038/sj.onc.1204608 CrossRefPubMed

33.

Bradley E, Ruan M, Oursler MJ (2008) Novel pro-survival functions of the Kruppel-like transcription factor Egr2 in promotion of macrophage colony-stimulating factor-mediated osteoclast survival downstream of the MEK/ERK pathway. J Biol Chem 283(12):8055–8064CrossRefPubMed

34.

Levi G, Topilko P, Schneider-Maunoury S, Lasagna M, Mantero S, Cancedda R, Charnay P (1996) Defective bone formation in Krox-20 mutant mice. Development 122(1):113–120PubMed

35.

Miano JM (2003) Serum response factor: toggling between disparate programs of gene expression. J Mol Cell Cardiol 35(6):577–593CrossRefPubMed

36.

Li S, Czubryt MP, McAnally J, Bassel-Duby R, Richardson JA, Wiebel FF, Nordheim A, Olson EN (2005) Requirement for serum response factor for skeletal muscle growth and maturation revealed by tissue-specific gene deletion in mice. Proc Natl Acad Sci U S A 102(4):1082–1087. https://doi.org/10.1073/pnas.0409103102 CrossRefPubMedPubMedCentral

37.

Chen J, Yuan K, Mao X, Miano JM, Wu H, Chen Y (2012) Serum response factor regulates bone formation via IGF-1 and Runx2 signals. J Bone Miner Res Off J Am Soc Bone Miner Res 27(8):1659–1668. https://doi.org/10.1002/jbmr.1607 CrossRef

38.

Chandar N, Saluja R, Lamar PC, Kolman K, Prozialeck WC (2005) P53 and beta-catenin activity during estrogen treatment of osteoblasts. Cancer Cell Int 5(24). https://doi.org/10.1186/1475-2867-5-24

39.

Mendoza S, Konishi T, Dernell WS, Withrow SJ, Miller CW (1998) Status of the p53, Rb and MDM2 genes in canine osteosarcoma. Anticancer Res 18(6a):4449–4453PubMed

40.

Bongiovanni L, Mazzocchetti F, Malatesta D, Romanucci M, Ciccarelli A, Buracco P, De Maria R, Palmieri C, Martano M, Morello E, Maniscalco L, Della Salda L (2012) Immunohistochemical investigation of cell cycle and apoptosis regulators (survivin, beta-catenin, p53, caspase 3) in canine appendicular osteosarcoma. BMC Vet Res 8:78. https://doi.org/10.1186/1746-6148-8-78 CrossRefPubMedPubMedCentral

41.

Angulo P, Kaushik G, Subramaniam D, Dandawate P, Neville K, Chastain K, Anant S (2017) Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy. J Hematol Oncol 10(1):10. https://doi.org/10.1186/s13045-016-0373-z CrossRefPubMedPubMedCentral

42.

Thomas DM (2010) Wnts, bone and cancer. J Pathol 220(1):1–4. https://doi.org/10.1002/path.2635 CrossRefPubMed

43.

Iwaya K, Ogawa H, Kuroda M, Izumi M, Ishida T, Mukai K (2003) Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis 20(6):525–529CrossRefPubMed

44.

Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, Ehrich M, Dobrovic A, Slavin J, Choong PF, Simmons PJ, Dawid IB, Thomas DM (2009) Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 119(4):837–851. https://doi.org/10.1172/jci37175 CrossRefPubMedPubMedCentral

45.

Hoang BH, Kubo T, Healey JH, Yang R, Nathan SS, Kolb EA, Mazza B, Meyers PA, Gorlick R (2004) Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res 64(8):2734–2739CrossRefPubMed

46.

Guo Y, Zi X, Koontz Z, Kim A, Xie J, Gorlick R, Holcombe RF, Hoang BH (2007) Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J Orthop Res 25(7):964–971. https://doi.org/10.1002/jor.20356 CrossRefPubMed

Title: Identification of Differentially Expressed Genes under the Regulation of Transcription Factors in Osteosarcoma
Authors: Yang Liu
Jianzhong Guan
Xiaotian Chen
Publication date: 01-07-2019
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 3/2019
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-018-0519-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2019

Ultrasound Risk Assessment Combined with Molecular Markers of Galectin-3, c-MET, HBME-1 and CK19 for Diagnosis of Malignant and Benign Thyroid Nodules

Local Interleukin-2 Immunotherapy of Breast Cancer: Benefit and Risk in a Spontaneous Mouse Model

Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia

Androgen Receptor Predicts First and Multiple Recurrences in Non-Muscle Invasive Urothelial Carcinoma of the Bladder

Thyroid Carcinoma Coexisting with Hashimoto’s Thyreoiditis: Clinicopathological and Molecular Characteristics Clue up Pathogenesis

Interaction of Breast Cancer and Insulin Resistance on PD1 and TIM3 Expression in Peripheral Blood CD8 T Cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer